iRhythm Reports Strong Q4 Earnings Growth Amid Market Strength
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 12 2026
0mins
Source: stocktwits
iRhythm Holdings, Inc. shares fell 3.81% and hit a 20-day low despite the Nasdaq-100 rising 0.99% and the S&P 500 increasing 0.66%.
The company reported a strong Q4 2025 earnings growth, with revenue of $208.9 million, a 27.1% year-over-year increase, and a net income of $5.6 million, marking its first positive quarterly net income. iRhythm also expects 2026 revenue to range between $870 million and $880 million, reflecting confidence in sustained growth and profitability. However, the stock's decline is attributed to sector rotation, as broader market strength did not translate to gains for iRhythm.
This performance highlights iRhythm's solid market position and growth potential in the cardiac monitoring sector, but the stock's current trajectory suggests a disconnect between company performance and market sentiment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IRTC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IRTC
Wall Street analysts forecast IRTC stock price to rise
13 Analyst Rating
12 Buy
1 Hold
0 Sell
Strong Buy
Current: 126.030
Low
205.00
Averages
222.00
High
244.00
Current: 126.030
Low
205.00
Averages
222.00
High
244.00
About IRTC
iRhythm Holdings, Inc. is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. The Company's principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. The Company provides Zio ambulatory cardiac monitoring services, including long-term continuous monitoring (LTCM), short-term continuous monitoring, and mobile cardiac telemetry (MCT) monitoring services, using a proprietary system that combines an FDA-cleared and CE-marked wire-free, patch-based, 14-day wearable biosensor that continuously records ECG data, with a proprietary FDA-cleared, CE-marked, Japan PDMA approved cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investigation into iRhythm Shareholder Rights
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether certain officers and directors of iRhythm Technologies, Inc. breached their fiduciary duties, which could impact corporate governance and shareholder rights.
- Legal Fee Arrangement: The firm operates on a contingent fee basis, meaning shareholders pursuing legal remedies will not incur out-of-pocket expenses, thereby lowering the barrier to participation in the investigation.
- Importance of Shareholder Participation: Encouraging shareholder involvement can enhance company policies and oversight mechanisms, increasing transparency and accountability, which ultimately boosts shareholder value and underscores the need for effective corporate governance.
- Historical Success Cases: Halper Sadeh LLC has successfully implemented corporate reforms and recovered millions for investors affected by securities fraud and corporate misconduct, demonstrating its effectiveness in protecting investor rights.
See More
Kuehn Law Investigates iRhythm Executives for Breach of Fiduciary Duties
- Legal Investigation Launched: Kuehn Law, PLLC is investigating whether executives at iRhythm Technologies, Inc. breached their fiduciary duties to shareholders, as a federal securities lawsuit alleges that insiders failed to disclose the true purpose of the Zio AT monitor, resulting in shareholder harm.
- Impact of Misrepresentation: The lawsuit claims that iRhythm executives exaggerated the market potential of the Zio AT as an innovative product without revealing it was designed for high-risk patients, leading to artificially inflated stock prices during relevant periods.
- Shareholder Rights Protection: Kuehn Law urges shareholders who purchased IRTC stock before November 5, 2021, to contact the firm promptly to protect their rights, highlighting the urgency of legal action and the firm's commitment to shareholder interests.
- Call for Market Integrity: Kuehn Law emphasizes that shareholder participation is crucial for maintaining the integrity and fairness of financial markets, encouraging investors to get involved to ensure the legality of their investments and safeguard their future.
See More
Kuehn Law Investigates iRhythm Executives for Breach of Fiduciary Duties
- Investigation Background: Kuehn Law, PLLC is investigating whether certain officers and directors of iRhythm Technologies, Inc. breached their fiduciary duties to shareholders, as a federal securities lawsuit alleges that insiders failed to disclose the true purpose of the Zio AT monitor, leading to artificially inflated stock prices.
- Product Misrepresentation: The lawsuit claims that insiders at iRhythm repeatedly touted the potential growth of the Zio AT as an innovative product that had just begun penetrating the market for real-time monitoring of high-risk patients, misleading investors regarding its premium pricing.
- Stock Price Impact: As a result of these misrepresentations, iRhythm's common stock traded at artificially inflated prices during relevant periods, exposing shareholders to potential financial losses and undermining market fairness and transparency.
- Call to Action for Shareholders: Kuehn Law urges shareholders who purchased IRTC stock prior to November 5, 2021, to contact them promptly to enforce their rights and participate in actions aimed at maintaining the integrity of financial markets.
See More
Kuehn Law Investigates iRhythm Executives for Breach of Fiduciary Duties
- Shareholder Lawsuit Investigation: Kuehn Law, PLLC is investigating whether certain executives at iRhythm Technologies, Inc. breached their fiduciary duties to shareholders, with allegations that insiders failed to disclose the true purpose of the Zio AT monitor, resulting in shareholder harm.
- Impact of Misrepresentation: The lawsuit claims that insiders at iRhythm repeatedly exaggerated the market potential of the Zio AT as an innovative product, leading to artificially inflated stock prices during relevant periods, which misled investors in their decision-making.
- Investor Rights Protection: Kuehn Law urges shareholders who purchased IRTC stock before November 5, 2021, to contact the firm promptly to enforce their rights within a limited timeframe, emphasizing the importance of shareholder voices in maintaining integrity in financial markets.
- Legal Costs Covered: Kuehn Law states that it will cover all case costs and does not charge its investor clients, aiming to encourage more shareholders to participate in the lawsuit to uphold fairness and integrity in the market.
See More
Ventripoint Joins Global Congenital Heart Disease Alliance to Enhance Care Access
- Growing Market Demand: The 2026 World Heart Report indicates that congenital heart disease now affects approximately 16 million people globally, up from 11.8 million three decades ago, highlighting the urgent need for advanced diagnostic technologies, particularly in low-income regions.
- Technological Innovation: Ventripoint's VMS+™ platform utilizes artificial intelligence to convert standard 2D echocardiograms into highly accurate 3D heart models, delivering MRI-level measurement accuracy to address the limitations of traditional imaging techniques in complex anatomical structures.
- Global Collaboration: Ventripoint announced its support for the newly formed Global Congenital Heart Disease Alliance (GCHDA) and plans to provide four VMS+™ units to directly support congenital heart disease patients, thereby expanding access to advanced diagnostic care.
- Broad Market Prospects: The echocardiography market is projected to reach approximately $2.64 billion by 2030, positioning Ventripoint favorably in the rapidly growing medical technology sector, especially as AI-driven cardiac imaging technologies gain increasing attention.
See More
iRhythm Addresses Cybersecurity Incident Impact
- Cybersecurity Incident Overview: iRhythm Holdings detected suspicious activity on June 8 involving its third-party-hosted business applications, prompting the initiation of its cybersecurity response plan; despite the material volume of potentially leaked information, the company reports no substantial impact on its business operations.
- Ransom Demand from Threat Actor: Following the incident, a threat actor demanded payment to prevent the disclosure of sensitive information, including patient data; however, iRhythm confirmed that its clinical or medical device systems were unaffected, ensuring customer safety.
- Financial Impact Assessment: iRhythm emphasized that while the volume of potentially leaked information is significant, the presence of cybersecurity insurance means the incident is unlikely to materially affect its financial position or operating results, thereby maintaining investor confidence.
- Future Outlook: iRhythm forecasts revenue for 2026 to be between $875 million and $885 million, targeting an adjusted EBITDA margin of 12%-13%, demonstrating the company's resilience and growth potential in the face of challenges.
See More
Investigation into iRhythm Shareholder Rights
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether certain officers and directors of iRhythm Technologies, Inc. breached their fiduciary duties, which could impact corporate governance and shareholder rights.
- Legal Fee Arrangement: The firm operates on a contingent fee basis, meaning shareholders pursuing legal remedies will not incur out-of-pocket expenses, thereby lowering the barrier to participation in the investigation.
- Importance of Shareholder Participation: Encouraging shareholder involvement can enhance company policies and oversight mechanisms, increasing transparency and accountability, which ultimately boosts shareholder value and underscores the need for effective corporate governance.
- Historical Success Cases: Halper Sadeh LLC has successfully implemented corporate reforms and recovered millions for investors affected by securities fraud and corporate misconduct, demonstrating its effectiveness in protecting investor rights.
See More
Kuehn Law Investigates iRhythm Executives for Breach of Fiduciary Duties
- Legal Investigation Launched: Kuehn Law, PLLC is investigating whether executives at iRhythm Technologies, Inc. breached their fiduciary duties to shareholders, as a federal securities lawsuit alleges that insiders failed to disclose the true purpose of the Zio AT monitor, resulting in shareholder harm.
- Impact of Misrepresentation: The lawsuit claims that iRhythm executives exaggerated the market potential of the Zio AT as an innovative product without revealing it was designed for high-risk patients, leading to artificially inflated stock prices during relevant periods.
- Shareholder Rights Protection: Kuehn Law urges shareholders who purchased IRTC stock before November 5, 2021, to contact the firm promptly to protect their rights, highlighting the urgency of legal action and the firm's commitment to shareholder interests.
- Call for Market Integrity: Kuehn Law emphasizes that shareholder participation is crucial for maintaining the integrity and fairness of financial markets, encouraging investors to get involved to ensure the legality of their investments and safeguard their future.
See More
Kuehn Law Investigates iRhythm Executives for Breach of Fiduciary Duties
- Investigation Background: Kuehn Law, PLLC is investigating whether certain officers and directors of iRhythm Technologies, Inc. breached their fiduciary duties to shareholders, as a federal securities lawsuit alleges that insiders failed to disclose the true purpose of the Zio AT monitor, leading to artificially inflated stock prices.
- Product Misrepresentation: The lawsuit claims that insiders at iRhythm repeatedly touted the potential growth of the Zio AT as an innovative product that had just begun penetrating the market for real-time monitoring of high-risk patients, misleading investors regarding its premium pricing.
- Stock Price Impact: As a result of these misrepresentations, iRhythm's common stock traded at artificially inflated prices during relevant periods, exposing shareholders to potential financial losses and undermining market fairness and transparency.
- Call to Action for Shareholders: Kuehn Law urges shareholders who purchased IRTC stock prior to November 5, 2021, to contact them promptly to enforce their rights and participate in actions aimed at maintaining the integrity of financial markets.
See More
Kuehn Law Investigates iRhythm Executives for Breach of Fiduciary Duties
- Shareholder Lawsuit Investigation: Kuehn Law, PLLC is investigating whether certain executives at iRhythm Technologies, Inc. breached their fiduciary duties to shareholders, with allegations that insiders failed to disclose the true purpose of the Zio AT monitor, resulting in shareholder harm.
- Impact of Misrepresentation: The lawsuit claims that insiders at iRhythm repeatedly exaggerated the market potential of the Zio AT as an innovative product, leading to artificially inflated stock prices during relevant periods, which misled investors in their decision-making.
- Investor Rights Protection: Kuehn Law urges shareholders who purchased IRTC stock before November 5, 2021, to contact the firm promptly to enforce their rights within a limited timeframe, emphasizing the importance of shareholder voices in maintaining integrity in financial markets.
- Legal Costs Covered: Kuehn Law states that it will cover all case costs and does not charge its investor clients, aiming to encourage more shareholders to participate in the lawsuit to uphold fairness and integrity in the market.
See More
Ventripoint Joins Global Congenital Heart Disease Alliance to Enhance Care Access
- Growing Market Demand: The 2026 World Heart Report indicates that congenital heart disease now affects approximately 16 million people globally, up from 11.8 million three decades ago, highlighting the urgent need for advanced diagnostic technologies, particularly in low-income regions.
- Technological Innovation: Ventripoint's VMS+™ platform utilizes artificial intelligence to convert standard 2D echocardiograms into highly accurate 3D heart models, delivering MRI-level measurement accuracy to address the limitations of traditional imaging techniques in complex anatomical structures.
- Global Collaboration: Ventripoint announced its support for the newly formed Global Congenital Heart Disease Alliance (GCHDA) and plans to provide four VMS+™ units to directly support congenital heart disease patients, thereby expanding access to advanced diagnostic care.
- Broad Market Prospects: The echocardiography market is projected to reach approximately $2.64 billion by 2030, positioning Ventripoint favorably in the rapidly growing medical technology sector, especially as AI-driven cardiac imaging technologies gain increasing attention.
See More
iRhythm Addresses Cybersecurity Incident Impact
- Cybersecurity Incident Overview: iRhythm Holdings detected suspicious activity on June 8 involving its third-party-hosted business applications, prompting the initiation of its cybersecurity response plan; despite the material volume of potentially leaked information, the company reports no substantial impact on its business operations.
- Ransom Demand from Threat Actor: Following the incident, a threat actor demanded payment to prevent the disclosure of sensitive information, including patient data; however, iRhythm confirmed that its clinical or medical device systems were unaffected, ensuring customer safety.
- Financial Impact Assessment: iRhythm emphasized that while the volume of potentially leaked information is significant, the presence of cybersecurity insurance means the incident is unlikely to materially affect its financial position or operating results, thereby maintaining investor confidence.
- Future Outlook: iRhythm forecasts revenue for 2026 to be between $875 million and $885 million, targeting an adjusted EBITDA margin of 12%-13%, demonstrating the company's resilience and growth potential in the face of challenges.
See More
